• About us
• Contact

Advertisement

Organisation › Details

Genevant Sciences Inc.

Genevant Sciences aims to deliver innovative and clinically meaningful therapies that improve the lives of patients with genetic disorders by developing products in-house and forming partnerships to build a diverse pipeline of RNA therapeutics across multiple modalities. Through its proprietary delivery platforms, Genevant is able to pursue mRNA, RNAi, and gene editing modalities and select the optimal approach for any given disease. Genevant expects to have 5 to 10 RNA programs in the clinic by 2020 targeting a range of genetic disorders with limited or no treatment options. *

 

	Start	2018-07-10 existent
	Group	Roivant (Group)
	Industry	RNA-based therapeutic
	Industry 2	mRNA technology
	Person	Panayiotopoulos, Paris (Blackstone 20911 Managing Director of Blackstone Life Sciences before Genevant + Ariad)
	Region	Cambridge, MA
	Country	United States (USA)
	City	n. a.
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: BioNTech AG. (7/10/18). "Press Release: BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases". Mainz, Cambridge, MA & Basel.
		Record changed: 2023-07-10

Advertisement

More documents for Roivant (Group)

• [1] VantAI. (2/13/24). "Press Release: VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence". New York, NY....
• [2] VantAI. (2/7/24). "Press Release: VantAI Appoints Jae Won Kim as Chief Operating Officer and Chief Financial Officer". New York, NY....
• [3] Roche. (10/23/23). "Press Release: Roche Enters into a Definitive Agreement to Acquire Telavant". Basel....
• [4] VantAI. (4/20/22). "Press Release: VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders". new York, NY & Ingelheim....
• [5] Affimed N.V.. (3/31/22). "Press Release: Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress". Heidelberg....
• [6] Roivant Sciences GmbH. (2/26/21). "Press Release: Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics". New York, NY, Boston, MA & Basel....
• [7] Medigene AG. (11/12/20). "Press Release: Medigene Provides Q3 2020 Update". Planegg-Martinsried....
• [8] Medigene AG. (10/19/20). "Press Release: Medigene and Cytovant Enter into Service Agreement for DC Vaccine Manufacturing Process Development". Planegg-Martinsried....
• [9] Roivant Sciences GmbH. (10/31/19). "Press Release: Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance". Tokyo, Osaka, London & Basel....
• [10] Roivant Sciences GmbH. (10/9/19). "Press Release: Parexel and Datavant Enter Multi-Year Strategic Partnership to Enable the Connection of Real-World Data Across All Parexel Clinical Trials". Boston, MA & San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.